Rhumbline Advisers Instil Bio, Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$0.4 - $0.63 $3,427 - $5,398	-8,569 Reduced 78.91%	2,290 $0
Q2 2023 Aug 08, 2023	SELL	$0.51 - $0.67 $48,754 - $64,049	-95,597 Reduced 89.8%	10,859 $5,000
Q1 2023 May 11, 2023	BUY	$0.6 - $0.91 $1,332 - $2,020	2,220 Added 2.13%	106,456 $70,000
Q4 2022 Feb 14, 2023	SELL	$0.48 - $5.33 $170 - $1,897	-356 Reduced 0.34%	104,236 $66,000
Q3 2022 Nov 10, 2022	BUY	$4.65 - $7.37 $27,016 - $42,819	5,810 Added 5.88%	104,592 $506,000
Q2 2022 Aug 11, 2022	BUY	$4.21 - $11.15 $153,037 - $405,313	36,351 Added 58.23%	98,782 $456,000
Q1 2022 May 12, 2022	BUY	$8.48 - $18.1 $30,968 - $66,101	3,652 Added 6.21%	62,431 $671,000
Q4 2021 Feb 10, 2022	BUY	$15.37 - $22.5 $641,589 - $939,217	41,743 Added 245.03%	58,779 $1.01 Million
Q3 2021 Nov 12, 2021	BUY	$15.05 - $23.28 $14,914 - $23,070	991 Added 6.18%	17,036 $305,000
Q2 2021 Aug 05, 2021	BUY	$15.31 - $24.63 $245,648 - $395,188	16,045 New	16,045 $310,000

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $2.01B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.